TP53 and acute myeloid leukemia: To confirm that the therapy response is indeed dependent on E177R expression, we generated an isogenic LSL-E177R;CreERT2 AML cell clone with stable Cas9 expression and subsequently transduced this clone with lentiviruses expressing either a Trp53-targeting (sg-p53) or a non-targeting scrambled sgRNA (sg-scr).